Rigel Pharmaceuticals (RIGL) PT Raised to $11 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Rigel Pharma (RIGL) Pushes to Highs; Shares Up 53%
August 30, 2016 12:37 PM EDTRigel Pharma (NASDAQ: RIGL) pushes to the highs of the session. Shares are up 53% to $4.03.
... MoreRigel Pharma (RIGL) Sees Wild Rollercoaster Pre-Open Trading Amid Data
August 30, 2016 8:43 AM EDTRigel Pharma (NASDAQ: RIGL) is seeing wild gyrations in pre-open trade following this morning's... More
Rigel Pharmaceuticals (RIGL) PT Raised to $6 at BMO Capital Following Positive ITP Study
August 30, 2016 8:21 AM EDTBMO Capital analyst Do Kim reiterated an Outperform rating and raised his price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $6.00 (from $4.00) following positive results from the first of two Phase III trials for fostamatinib in chronic ITP.
"We believe the significant 18% response rate... More
Rigel Pharma (RIGL) Could Rise Up to 90% Today - JP Morgan
August 30, 2016 7:27 AM EDTJPMorgan is making positive comments on Rigel Pharma (NASDAQ: RIGL) following this morning's phase 3 data and said the stock could rise 60-90% today.
... MoreRigel Pharma (RIGL) Oral Spleen Tyrosine Kinase (SYK) Inhibitor Met Primary Endpoint in Phase 3 Study
August 30, 2016 7:01 AM EDTRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, met the primary endpoint in the first of two double-blind studies in the FIT Phase 3 clinical program for the treatment of adult chronic/persistent immune thrombocytopenia (ITP). The study (n=76) showed that 18% of patients receiving fostamatinib achieved a stable platelet response compared to none receiving a placebo control (p=0.0261). A stable platelet response was defined as achieving greater than 50,000 platelets per uL of blood on at least four of the last six scheduled visits between weeks 14 and 24... More
